IP Library Granted Patent US 10,973,810
Granted Patent B2
US 10,973,810 · App. 15/863,773 · Granted Apr 13, 2021

Methods for the treatment of neurological disorders

Inventors: Benjamin Vincent (Cambridge, MA); Daniel Tardiff (Arlington, MA); Jeff Piotrowski (Somerville, MA); Eric Solis (Milford, MA); Robert Scannevin (Hopkinton, MA); Chee-Yeun Chung (Brookline, MA); Rebecca Aron (Cambridge, MA); Bertrand Le Bourdonnec (Northborough, MA); Matthew Lucas (Lexington, MA); Kenneth Rhodes (Belmont, MA)
Assignee: Yumanity Therapeutics, Inc.
A61K31/454A61K31/4545A61K45/06A61P25/14A61P25/16A61P25/28G01N33/6896G01N2333/46G01N2333/775G01N2800/28G01N2800/285G01N2800/2814G01N2800/2821G01N2800/2828G01N2800/2835
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,810
App. No.
15/863,773
Granted
Apr 13, 2021
Kind
B2
Abstract

The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Claims (10)

1. A method of treating a Parkinson's disease or Lewy body dementia in a subject in need thereof, the method comprising administering an effective amount of an SCD5 inhibitor to the subject.

2. A method of treating a Parkinson's disease or Lewy body dementia in a subject in need thereof, the method comprising administering an effective amount of an inhibitor of SCD5 and SCD1 to the subject.

3. The method of claim 1 , wherein the subject carries one or two copies of the ApoE4 allele.

4. The method of claim 1 , wherein the method further comprises administering an additional therapeutic agent to the subject.

5. The method of claim 4 , wherein the additional therapeutic agent is a small molecule, an antibody or fragment thereof, or a nucleic acid.

6. The method of claim 4 , wherein the additional therapeutic agent is a cognition-enhancing agent, an antidepressant agent, an anxiolytic agent, an antipsychotic agent, a sedative, a dopamine promoter, or an anti-tremor agent.

7. The method of claim 2 , wherein the subject carries one or two copies of the ApoE4 allele.

8. The method of claim 2 , wherein the method further comprises administering an additional therapeutic agent to the subject.

9. The method of claim 8 , wherein the additional therapeutic agent is a small molecule, an antibody or fragment thereof, or a nucleic acid.

10. The method of claim 9 , wherein the additional therapeutic agent is a cognition-enhancing agent, an antidepressant agent, an anxiolytic agent, an antipsychotic agent, a sedative, a dopamine promoter, or an anti-tremor agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: YUMANITY THERAPEUTICS, INC.; YUMANITY, INC.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 062148/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2020
From: VINCENT, BENJAMIN; TARDIFF, DANIEL; PIOTROWSKI, JEFF; SOLIS, ERIC; SCANNEVIN, ROBERT; CHUNG, CHEE-YEUN; ARON, REBECCA; LE BOURDONNEC, BERTRAND; LUCAS, MATTHEW; RHODES, KENNETH
To: YUMANITY THERAPEUTICS, INC.
Reel/Frame 054325/0227 →
Continuity (2)
Provisional Application 62443066 · Jan 6, 2017
Related Publication 20180193325A1 · Jul 12, 2018
Cited By (3)
US 12,268,687 US 12,275,723 US 12,433,880